AAO/PAAO: Intravitreal Injection of Triamcinolone Acetonide Improves Visual Acuity in Patients with Diffuse Diabetic Macular Ooedema
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




AAO/PAAO: Intravitreal Injection of Triamcinolone Acetonide Improves Visual Acuity in Patients with Diffuse Diabetic Macular Ooedema

By Anne Jacobson
Special to DG News

ORLANDO, FL -- October 22, 2002 -- Intravitreal injection of 25 mg triamcinolone acetonide is an effective treatment for clinically significant diffuse diabetic macular oedema, new research suggests.

Jost B. Jonas, MD, of the department of ophthalmology and eye hospital at the Friedrich-Alexander-University Erlangen-Nürnberg, in Erlangen, Germany, reported his findings here October 20 at the Joint Meeting of the American Academy of Ophthalmology and the Pan-American Association of Ophthalmology (AAO/PAAO).

In this prospective study, Dr. Jonas evaluated 15 patients who received an intravitreal injection of 25 mg triamcinolone acetonide for treatment of diffuse diabetic macular oedema over a mean follow-up time of 5.2 months.

Following treatment, visual acuity increased significantly from an average 0.08 at baseline to a maximum of 0.16 (p=0.004) at follow-up. Visual acuity improved by six weeks after treatment to an average 0.13 (p=0.003) and to 0.16 (p=0.018) by six months.

Overall, nine eyes (90 percent) observed for at least one month were found to gain visual acuity.

According to Dr. Jonas, the 25 mg dose used in this study is significantly higher than the 4 mg dose commonly used in clinical practice. Dr. Jonas says he believes that the frequencies of side effects are similar at the two doses, but that the 25 mg dose results in a much longer duration of effect.

"We repeat the injections at four to nine months in all patients who experience an increase in visual acuity with the initial injection," Dr. Jonas told Doctor’s Guide. In some patients who receive the 25 mg injection, the resulting increase in visual acuity persists for up to nine months.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities